Endocrine gastroenterological aspects of metabolic dysfunction
https://doi.org/10.31146/1682-8658-ecg-229-9-36-43
Abstract
This review article examines the endocrine gastroenterological aspects of metabolic dysfunction, which is a complex pathological condition that affects metabolism and is accompanied by disturbances in the functioning of the endocrine system. The introduction focuses on key hormones such as insulin and leptin and their roles in regulating metabolism and digestive processes. The consequences of disturbances in the secretion of these hormones, including the development of type 2 diabetes mellitus and obesity, are discussed. The article offers a comprehensive analysis of the relationship between endocrine disruption and gastroenterological problems such as irritable bowel syndrome, highlighting the importance of further research to understand the mechanisms underlying these diseases. The results of this review can serve as the basis for the development of new approaches to the diagnosis and treatment of metabolic disorders, as well as for the formation of strategies for the prevention of associated diseases.
About the Authors
T. I. Chernyadyeva
Mari State University
Russian Federation
Russian Federation
R. A. Bontsevich
Mari State University; Belgorod National Research University; Kazan State Medical Academy - branch of the Federal State Budgetary Educational Institution of Further Professional Education RMANPO
Russian Federation
Russian Federation
O. V. Gaus
Omsk State Medical University
Russian Federation
Russian Federation
References
1. Semnani S, Roshandel G, Keshtkar A, et al. Serum leptin levels and irritable bowel syndrome: a new hypothesis. J Clin Gastroenterol. 2009;43(9):826-830. doi: 10.1097/MCG.0b013e3181986900 Semnani S, Roshandel G, Keshtkar A, et al. Serum leptin levels and irritable bowel syndrome: a new hypothesis. J Clin Gastroenterol. 2009;43(9):826-830. doi: 10.1097/MCG.0b013e3181986900.
2. Drapkina O.M., Kim O.T. Is brown adipose tissue a new target for obesity therapy? Cardiovascular Therapy and Prevention. 2021;20(5):2860. (In Russ.) doi: 10.15829/1728-8800-2021-2860.@@ Драпкина О.М., Ким О.Т. Бурая жировая ткань - новая мишень борьбы с ожирением? Кардиоваскулярная терапия и профилактика. 2021;20(5):2860. doi: 10.15829/1728-8800-2021-2860.
3. Maksimov M.L., Filimonova I.M., Shikaleva A.A., Knni Yu.A., Kanunikova E.A., Kanner E.V., Bontsevich R.A. Current issues of diabetes mellitus pharmacotherapy. Clinical pharmacology of hypoglycemic drugs. Textbook for doctors. Kazan, 2023. (in Russ.)@@ Актуальные вопросы фармакотерапии сахарного диабета. Клиническая фармакология сахароснижающих препаратов. Максимов М.Л., Филимонова И.М., Шикалева А.А., Кнни Ю.А., Кануникова Е.А., Каннер Е.В., Бонцевич Р.А. Учебное пособие для врачей / Казань, 2023.
4. Mir MM, Mir R, Alghamdi MAA, et al. Differential Association of Selected Adipocytokines, Adiponectin, Leptin, Resistin, Visfatin and Chemerin, with the Pathogenesis and Progression of Type 2 Diabetes Mellitus (T2DM) in the Asir Region of Saudi Arabia: A Case Control Study. J Pers Med. 2022;12(5):735. Published 2022 May 1. doi: 10.3390/jpm12050735.
5. Chen L, Xuan Y, Zhu Y, et al. Adipocyte secreted NRG4 ameliorates age-associated metabolic dysfunction. Biochem Pharmacol. 2024;225:116327. doi: 10.1016/j.bcp.2024.116327.
6. Baldelli S, Aiello G, Mansilla Di Martino E, Campaci D, Muthanna FMS, Lombardo M. The Role of Adipose Tissue and Nutrition in the Regulation of Adiponectin. Nutrients. 2024;16(15):2436. Published 2024 Jul 26. doi: 10.3390/nu16152436.
7. Longo L, Marschner RA, de Freitas LBR, et al. Redefining the Role of Ornithine Aspartate and Vitamin E in Metabolic-Dysfunction-Associated Steatotic Liver Disease through Its Biochemical Properties.Int J Mol Sci. 2024;25(13):6839. Published 2024 Jun 21. doi: 10.3390/ijms25136839.
8. Patrizio A, Ferrari SM, Elia G, et al. Hypothyroidism and metabolic cardiovascular disease. Front Endocrinol (Lausanne). 2024;15:1408684. Published 2024 Jun 3. doi: 10.3389/fendo.2024.1408684.
9. Olanrewaju OA, Asghar R, Makwana S, et al. Thyroid and Its Ripple Effect: Impact on Cardiac Structure, Function, and Outcomes. Cureus. 2024;16(1): e51574. Published 2024 Jan 3. doi: 10.7759/cureus.51574.
10. Fiore V, Barucca A, Barraco S, et al. Hypothyroidism in Older Adults: A Narrative Review. Endocr Metab Immune Disord Drug Targets. 2024;24(8):879-884. doi: 10.2174/1871530323666230828110153.
11. Wei Y, Li X, Cui R, Liu J, Wang G. Associations between sensitivity to thyroid hormones and insulin resistance in euthyroid adults with obesity. Front Endocrinol (Lausanne). 2024;15:1366830. Published 2024 Aug 8. doi: 10.3389/fendo.2024.1366830.
12. Jakubiak GK, Pawlas N, Morawiecka-Pietrzak M, Starzak M, Stanek A, Cieślar G. Retrospective Cross-Sectional Study of the Relationship of Thyroid Volume and Function with Anthropometric Measurements, Body Composition Analysis Parameters, and the Diagnosis of Metabolic Syndrome in Euthyroid People Aged 18-65. Medicina (Kaunas). 2024;60(7):1080. Published 2024 Jun 30. doi: 10.3390/medicina60071080.
13. Sagliocchi S, Restolfer F, Cossidente A, Dentice M. The key roles of thyroid hormone in mitochondrial regulation, at interface of human health and disease. J Basic Clin Physiol Pharmacol. Published online July 19, 2024. doi: 10.1515/jbcpp-2024-0108.
14. Thakur R, Kumar S, Neeraj RK, Saleem M, Kumar C, Mohan L. Evaluation of the Association between Insulin Resistance and Subclinical Hypothyroidism Using Triglyceride-Glucose Index: a Cross-Sectional Study. Maedica (Bucur). 2024;19(2):255-259. doi: 10.26574/maedica.2024.19.2.255.
15. Zhai X, Li Y, Teng X, Teng W, Shi X, Shan Z. Relationship Between Serum Thyrotropin Levels and Metabolic Diseases in Older Adults. J Clin Endocrinol Metab. Published online July 2, 2024. doi: 10.1210/clinem/dgae387.
16. Roszczyc-Owsiejczuk K, Imierska M, Sokołowska E, et al. shRNA-mediated down-regulation of Acsl1 reverses skeletal muscle insulin resistance in obese C57BL6/J mice. PLoS One. 2024;19(8): e0307802. Published 2024 Aug 23. doi: 10.1371/journal.pone.0307802.
17. Oltmanns KM, Dodt B, Schultes B, et al. Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur J Endocrinol. 2006;154(2):325-331. doi: 10.1530/eje.1.02074.
18. Piątkowska-Chmiel I, Krawiec P, Ziętara KJ, et al. The Impact of Chronic Stress Related to COVID-19 on Eating Behaviors and the Risk of Obesity in Children and Adolescents. Nutrients. 2023;16(1):54. Published 2023 Dec 23. doi: 10.3390/nu16010054.
19. Romaní-Pérez M, Líebana-García R, Flor-Duro A, et al. Obesity and the gut microbiota: implications of neuroendocrine and immune signaling. FEBS J. Published online August 19, 2024. doi: 10.1111/febs.17249.
20. Battista F, Bettini S, Verde L, Busetto L, Barrea L, Muscogiuri G. Diet and physical exercise in elderly people with obesity: The state of the art. Eur J Intern Med. Published online August 17, 2024. doi: 10.1016/j.ejim.2024.08.007.
21. Akhmedov VA, Gaus OV. Involvement of the hepatobiliary system and pancreas in obesity. Therapeutic Archive. 2017;89(1):128-133. (In Russ.) doi: 10.17116/terarkh2017891128-133.@@ Ахмедов В.А., Гаус О.В. Поражение органов гепатобилиарной системы и поджелудочной железы при ожирении. Терапевтический архив. 2017. Т. 89. № 1. С. 128-133. doi: 10.17116/terarkh2017891128-133.
22. Aggeletopoulou I, Tsounis EP, Triantos C. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.Int J Mol Sci. 2024;25(9):4901. Published 2024 Apr 30. doi: 10.3390/ijms25094901.
23. Szymala-Pędzik M, Piersiak M, Pachana M, Tomczak W, Sobieszczańska MI, Janocha A. Stłuszczenie wątroby jako czynnik ryzyka chorób sercowo-naczyniowych: analiza retrospektywna danych pacjentów Kliniki Geriatrii Uniwersyteckiego Szpitala Klinicznego we Wrocławiu [Fatty liver as a risk factor for cardiovascular diseases: retrospective analysis of data from patients of the Geriatrics Clinic of University Clinical Hospital in Wrocław]. Med Pr. 2024;75(3):223-231. doi: 10.13075/mp.5893.01510.
24. Lu H, Ban Z, Xiao K, et al. Hepatic-Accumulated Obeticholic Acid and Atorvastatin Self-Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic-Associated Fatty Liver Disease. Adv Sci (Weinh). 2024;11(10): e2308866. doi: 10.1002/advs.202308866.
25. Serbis A, Polyzos SA, Paschou SA, Siomou E, Kiortsis DN. Diet, exercise, and supplements: what is their role in the management of the metabolic dysfunction-associated steatotic liver disease in children?. Endocrine. 2024;85(3):988-1006. doi: 10.1007/s12020-024-03783-7.
26. Volarić M, Šojat D, Majnarić LT, Vučić D. The Association between Functional Dyspepsia and Metabolic Syndrome-The State of the Art.Int J Environ Res Public Health. 2024;21(2):237. Published 2024 Feb 18. doi: 10.3390/ijerph21020237.
27. Salgado-Delgado RC, Espinosa-Tanguma R, Valdés Abadía B, Ramírez-Plascencia OD, Escobar C, Saderi N. Feeding during the resting phase causes gastrointestinal tract dysfunction and desynchronization of metabolic and neuronal rhythms in rats. Neurogastroenterol Motil. 2023;35(12): e14687. doi: 10.1111/nmo.14687.
28. Pinelli M, Makdissi S, Scur M. et al. Peroxisomal cholesterol metabolism regulates yap-signaling, which maintains intestinal epithelial barrier function and is altered in Crohn’s disease. Cell Death Dis. 2024;15(7):536. Published 2024 Jul 28. doi: 10.1038/s41419-024-06925-x.
29. Casteels P, Kindt S. Diagnosing and managing irritable bowel syndrome with predominant diarrhoea in clinical practice: online survey among gastroenterologists and general practitioners. Acta Gastroenterol Belg. 2024;87(2):229-234. doi: 10.51821/87.2.12586.
30. Chlebicz-Wójcik A, Śliżewska K. Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review. Biomolecules. 2021;11(8):1154. Published 2021 Aug 4. doi: 10.3390/biom11081154.
31. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012 Aug 14;18(30):4012-8. doi: 10.3748/wjg.v18.i30.4012.
32. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006 Jul;101(7):1581-90. doi: 10.1111/j.1572-0241.2006.00734.x.
33. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011 May;33(10):1123-32. doi: 10.1111/j.1365-2036.2011.04633.x.
34. Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial. Biopsychosoc Med. 2012 Aug 3;6(1):16. doi: 10.1186/1751-0759-6-16.
35. Zhang Y, Wang S, Wang H, et al. Efficacy of Donor-Recipient-Matched Faecal Microbiota Transplantation in Patients with IBS-D: A Single-Centre, Randomized, Double-Blind Placebo-Controlled Study. Digestion. Published online July 31, 2024. doi: 10.1159/000540420.
36. Li C, Li J, Zhou Q, Wang C, Hu J, Liu C. Effects of Physical Exercise on the Microbiota in Irritable Bowel Syndrome. Nutrients. 2024;16(16):2657. Published 2024 Aug 11. doi: 10.3390/nu16162657.
37. Abraham P, Pratap N. Dysbiosis in Irritable Bowel Syndrome. J Assoc Physicians India. 2023;71(9):75-81. doi: 10.59556/japi.71.0353.
38. Akhmedov V.A., Gaus O.V. Modern views on development mechanisms and tactics for treatment of patients with gallbladder disease associated with metabolic syndrome. Medical alphabet. 2019;2(13):52-56. (In Russ.) doi: 10.33667/2078-5631-2019-2-13(388)-52-56.@@ Ахмедов В.А., Гаус О.В. Современные представления о механизмах развития и тактике ведения больных желчнокаменной болезнью, ассоциированной с метаболическим синдромом. Медицинский алфавит. 2019;2(13):52-56. doi: 10.33667/2078-5631-2019-2-13(388)-52-56.
39. Gaus O.V., Akhmedov V.A. Clinical, biochemical and immunological features of cholelithiasis associated with metabolic syndrome. Bulletin of the Novosibirsk State University. Series: Biology, clinical medicine. 2013;11(3):125-129. (in Russ.)@@ Гаус О.В., Ахмедов В.А. Клинико-биохимические и иммунологические особенности желчнокаменной болезни, ассоциированной с метаболическим синдромом. Вестник Новосибирского государственного университета. Серия: Биология, клиническая медицина. 2013. Т. 11. № 3. С. 125-129.
40. Gaus OV, Akhmedov VA. [Evaluation of prognostic factors for the development of cholelithiasis in patients with metabolic syndrome]. Eksp Klin Gastroenterol. 2014;(11):46-50. (in Russ.) PMID: 25842664.@@ Гаус О.В., Ахмедов В.А. Оценка прогностических факторов развития желчнокаменной болезни у лиц с метаболическим синдромом. Экспериментальная и клиническая гастроэнтерология. 2014. № 11 (111). С. 46-50.
Review
For citations:
Chernyadyeva T.I., Bontsevich R.A., Gaus O.V. Endocrine gastroenterological aspects of metabolic dysfunction. Experimental and Clinical Gastroenterology. 2024;(9):36-43. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-229-9-36-43
Views:
289
Email this article 